2012年5月
Downregulation of midkine induces cisplatin resistance in human oral squamous cell carcinoma
ONCOLOGY REPORTS
- 巻
- 27
- 号
- 5
- 開始ページ
- 1674
- 終了ページ
- 1680
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.3892/or.2012.1684
- 出版者・発行元
- SPANDIDOS PUBL LTD
The presence of drug-resistant cancer cells has been associated with poor clinical outcomes. Cisplatin is one of the most effective chemotherapeutic agents commonly used for several malignancies including oral squamous cell carcinoma (OSCC). Although cisplatin resistance is a major obstacle in cancer treatment, mechanisms by which it develops are not well understood. Midkine (MK), a heparin-binding growth factor, has various cancer-related functions. In this study, we investigated whether MK is involved in cisplatin resistance in OSCC. We demonstrated that the Sa-3R cell line, which is OSCC cisplatin-resistant, exhibited lower MK expression with slow growth compared with its parent, Sa-3 cells. In Sa-3 cells, downregulation of MK expression significantly reduced cisplatin sensitivity, cell growth, and the expression of cyclin D1 and cyclin El. MK knockdown suppressed cellular cisplatin accumulation via induction of ATP-binding cassette efflux transporters. These data suggest that MK may play important roles in cisplatin resistance in OSCC by modulating both cell growth and intracellular cisplatin accumulation.
- リンク情報
- ID情報
-
- DOI : 10.3892/or.2012.1684
- ISSN : 1021-335X
- eISSN : 1791-2431
- Web of Science ID : WOS:000302202600056